Gynion is a Women’s Health startup with a mission to offer millions of women worldwide safe, effective, and affordable in-office therapies for common gynecological conditions that improve and save lives.

Gynion is developing ablative gels for multiple indications in Women’s Health addressing unmet needs in several markets with a combined value of $69 Billion. Our therapeutic platform presents an opportunity to commercialize several products with an immediate focus on Clarablex for the treatment of cervical intraepithelial neoplasia (CIN) to prevent cervical cancer and Menorrx therapy for Heavy Menstrual Bleeding (HMB) to alleviate iron-deficiency anemia. Our future product Senoblex will offer an early treatment and prevention of breast cancer.

ClarablexTM is a topical gel for multiple indications in gynecology, including the treatment of cervical intraepithelial neoplasia (CIN) to prevent cervical cancer and other diseases caused by human papillomavirus (HPV). It is a simple and non-invasive treatment ready for immediate use by any healthcare provider trained in cervical cancer screening as soon as the woman is diagnosed with CIN. The low cost of Clarablex will permit all screening facilities, including those in low- and middle-income countries,  to keep it in the inventory removing all barriers to healthcare access and allowing more women to receive timely treatment preventing cervical cancer.

MenorrxTM is a therapy for Heavy Menstrual Bleeding (HMB). It is simpler, easier to use, and will cost significantly less than the alternatives. Because of the high cost and clinical limitations of the available options, millions of women receive no treatment or are compelled to undergo a hysterectomy. Menorrx presents a substantial opportunity to change that both in developed markets and low-resource countries.

Gynion

Org chart

Teams

Offices